產(chǎn)品編號(hào) | BIO0038SM |
英文名稱(chēng) | Anti-human ERBB2 / HER2 / CD340 (Pertuzumab Biosimilar) |
中文名稱(chēng) | |
抗體來(lái)源 | |
克隆類(lèi)型 | Monoclonal |
克 隆 號(hào) | |
交叉反應(yīng) | Human,Mouse,Cynomolgus |
產(chǎn)品應(yīng)用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
理論分子量 | 145.44 kDa |
檢測(cè)分子量 | |
性 狀 | Lyophilized |
亞 型 | Human IgG1 |
純化方法 | Protein A |
保存條件 | For long term storage, the produce should be stored at -20°C or lower. |
注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
PubMed | PubMed |
產(chǎn)品介紹 | |
產(chǎn)品圖片 |
Pertuzumab+trastuzumab inhibited the tumor growth of NCI-N87 on Balb/c nude mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 73.8% at 5 mpk at D37.
BT474 cells were stained with Anti-ERBB2 / HER2 / CD340 Reference Antibody (pertuzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.2994 ug/mL.
Immobilized human HER2(23 652) His at 2 ug/mL can bind Anti-ERBB2 / HER2 / CD340 Reference Antibody (pertuzumab), EC50=0.01375 ug/mL.
The purity of Anti-ERBB2 / HER2 / CD340 Reference Antibody (pertuzumab) is 99.02%, determined by SEC-HPLC.
|